Hong KongBiotech & Genomic Medicine▲impact 4
AstraZeneca Cancer Drug Targets Up to $5 Billion in Sales
AstraZeneca's investigational cancer drug sonesitatug vedotin could achieve peak annual sales between $3 billion and $5 billion after a late-stage trial met its primary overall-survival endpoint in advanced gastric cancer. The global Phase III study showed a clinically meaningful improvement in overall survival versus standard chemotherapy for patients receiving third-line or later treatment, and also met a key secondary overall-survival endpoint in the second-line or later setting. However, the drug did not reach statistical significance on its other primary endpoint of progression-free survival, though an improving trend was reported. The treatment was well tolerated with no new safety concerns. Sonesitatug vedotin is being developed by KYM Biosciences, a joint venture between Keymed Biosciences and Lepu Biopharma, in collaboration with AstraZeneca.
About megatrends
Biotech & Genomic Medicine › Antibody-Drug Conjugates (ADC) ▲Pricing
Biotech & Genomic Medicine › Oncology Therapeutics ▲Competition
AZN.LSE · Demand · Positive AstraZeneca's investigational drug sonesitatug vedotin met primary overall-survival endpoint in gastric cancer, with peak sales forecast of $3-5 billion.
KYM Biosciences · Demand · Positive KYM Biosciences is the developer of the drug; positive trial results and high sales forecast boost demand prospects.
2157.HK · Demand · Positive Lepu Biopharma, via its JV KYM Biosciences, co-develops the drug with AstraZeneca; positive trial results and high sales forecast boost demand prospects.
2162.HK · Demand · Positive Keymed Biosciences, via its JV KYM Biosciences, co-develops the drug; positive trial results and high sales forecast boost demand prospects.